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Much evidence now attests to the importance of desmosomes and their constituents in cancer. Alterations in the expression of
desmosomal components could contribute to the progression of the disease by modifying intracellular signal transduction pathways
and/or by causing reduced cell adhesion. The Wnt/b-catenin pathway is a potential target because of the involvement of the
cytoplasmic desmosomal protein plakoglobin. Loss of desmosomal adhesion is a prerequisite for the epithelial–mesenchymal
transition, implicated in the conversion of early stage tumours to invasive cancers.
British Journal of Cancer (2007) 96, 1783–1787. doi:10.1038/sj.bjc.6603808 www.bjcancer.com
Published online 22 May 2007
& 2007 Cancer Research UK
Keywords: desmosome; desmocollin; desmoglein; plakoglobin; EMT
                                
Desmosomes are intercellular junctions that confer strong
cell–cell adhesion. They are found in epithelia and cardiac muscle
and are located at the cell membrane, where they act as anchors
for intermediate filaments. Mutations in genes encoding desmo-
somal constituents can have devastating effects on tissue integrity,
but it would be a mistake to assume that desmosomes are
simply static adhesive structures; much evidence now indicates
that they play an important part in the regulation of cell
proliferation and differentiation. Furthermore, there is a strong
possibility that desmosomes influence epithelial cell invasion
and metastasis. The intention of this review is to concentrate on
the emerging evidence that implicates desmosomes in cancer.
Other substantive reviews that deal with desmosomes and their
role in other human diseases are available (Getsios et al, 2004;
Kottke et al, 2006).
DESMOSOME COMPOSITION
Desmosomes are made of proteins that belong to one of the three
gene families, the desmosomal cadherins, the armadillo family and
the plakin family of cytolinkers.
Desmosomal cadherins
The desmosomal cadherins are the membrane-spanning constitu-
ents of desmosomes, and in humans there are seven, three
desmocollins (Dsc1–3) and four desmogleins (Dsg1–4). All
desmosomes contain at least one desmocollin and one desmoglein
and both are required for adhesion. Each of the desmocollins exists
as a pair of proteins generated by alternative splicing, a longer ‘a’
form and a shorter ‘b’ form. It is not at all clear why the shorter
desmocollin ‘b’ proteins exist, or indeed why multiple desmocollin
and desmoglein genes are required. The desmosomal cadherins
show tissue-specific patterns of expression with Dsc2 and Dsg2
ubiquitously expressed in tissues that produce desmosomes, and
the other desmosomal cadherins largely restricted to stratified
epithelial tissues where they exhibit differentiation-specific
patterns of expression.
Armadillo family
Armadillo proteins found in desmosomes include plakoglobin
(g-catenin) and plakophilins. Plakoglobin is a cytoplasmic protein
that interacts with desmosomal cadherins, plakophilins and
desmoplakin (see below). It is found both in desmosomes and
adherens junctions where it is interchangeable with another
armadillo protein, b-catenin. In addition to having an important
structural role in cell junctions, plakoglobin acts as a signalling
molecule (see below). Plakophilins 1, 2 and 3 (PKP1–3) show
complex tissue-specific patterns of expression and dual localisa-
tion in desmosomes and in the nucleus. The details of their
structural role in desmosomes have yet to be worked out, but it
may be that the plakophilins are required to recruit desmoplakin
to the plasma membrane (Getsios et al, 2004).
Plakin family
Several plakin proteins, including desmoplakin, plectin, envopla-
kin and periplakin, localise to desmosomes. Of these, only
desmoplakin is obligatory for normal desmosomal adhesion.
Two isoforms of desmoplakin that are generated by alternative
splicing of a single transcript are known. These differ only in the
length of a central coiled-coil rod domain that separates N- and
C-terminal globular domains. It is now well established that the
N-terminal domain of desmoplakin binds to plakoglobin and
plakophilin, whereas its C-terminal domain interacts with inter-
mediate filaments (Getsios et al, 2004).
PLAKOGLOBIN AND WNT/b-CATENIN SIGNALLING
Desmosomes are not just static structural entities and many now
think of them as signalling centres. One of the ways that they could
modulate intracellular signal transduction is by regulating the
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www.bjcancer.comavailability of plakoglobin. Plakoglobin is closely related to
b-catenin, an important player in the Wnt/b-catenin pathway,
and both interact with many of the same molecules. In the
canonical pathway cytoplasmic b-catenin is phosphorylated by
glycogen synthase kinase 3b and targeted for proteosomal
degradation in the absence of a Wnt signal. Interaction of Wnts
with their receptors block phosphorylation of b-catenin and allow
it to accumulate in the cytoplasm and translocate to the nucleus,
where it converts DNA binding proteins of the T-cell factor (Tcf)/
lymphoid enhancer factor (Lef) family into transcriptional
activators. It is now well established that accumulation and
improper activation of transcriptional targets as a result of a
failure to degrade cytoplasmic b-catenin is associated with
tumours in a number of different tissues. More details of the
Wnt/b-catenin signalling pathway can be found elsewhere (Li et al,
2006).
The role of plakoglobin in the Wnt/b-catenin pathway is not as
defined as that of b-catenin. Like b-catenin, overexpression of
plakoglobin is able to induce anterior axis duplication in Xenopus
(Karnovsky and Klymkowsky, 1995) suggesting that it has a
b-catenin-like signalling activity. However, expression of mem-
brane-anchored forms of plakoglobin that show an exclusively
cytoplasmic localisation and are unable to enter the nucleus also
results in axis duplication (Merriam et al, 1997). This has led to the
suggestion that plakoglobin stimulates Wnt/b-catenin signalling
indirectly by blocking cytoplasmic degradation of b-catenin and
allowing its translocation to the nucleus. Topflash is a plasmid that
is used widely to measure Wnt/b-catenin signalling. It contains
three Tcf binding sites upstream of a minimal promoter and
luciferase reporter gene, and in many cases the increased Topflash
activity that has been observed in response to overexpression of
plakoglobin in transfected cells could be as a result of modifying
b-catenin degradation and/or subcellular localisation. Plakoglobin
can activate Topflash (all be it to a lesser extent than b-catenin),
and the cyclin D1 and Nr-CAM promoters, in b-catenin-null
embryonic stem cells showing that in some circumstances
plakoglobin can act as an activator of Wnt/b-catenin signalling
in its own right (as opposed to having an indirect effect via
b-catenin) (Conacci-Sorrell et al, 2002).
It may be that plakoglobin is actually a negative regulator of
Wnt/b-catenin signalling. Plakoglobin and b-catenin bind to
adjacent sites on Tcf-4 and plakoglobin inhibits binding of Tcf-4
to DNA (Miravet et al, 2002). Thus, plakoglobin could reduce
transcription of Wnt target genes by binding to Tcfs. In support of
this idea, suppression of desmoplakin expression in cardiac
myocytes (using small interfering RNA) leads to nuclear localisa-
tion of plakoglobin and suppression of Wnt/b-catenin signalling.
This in turn leads to a transcriptional switch from myogenesis to
adipogenesis and accumulation of fat droplets (Garcia-Gras et al,
2006). Conversely, phosphorylation of Tyr549 by the tyrosine
kinase Fer results in increased binding of plakoglobin to adherens
junctions and upregulation of Topflash activity (Miravet et al,
2003).
PLAKOGLOBIN AND CANCER
Plakoglobin appears to have both positive and negative effects
on cell growth. Thus, plakoglobin overexpression in transformed
rat kidney epithelial cells promotes unregulated growth and foci
formation (Kolligs et al, 2000). Unlike b-catenin, plakoglobin is a
strong activator of c-myc, which is thought to be essential for
plakoglobin’s transforming ability. Another suggestion is that
plakoglobin causes unregulated growth and foci formation
(in human squamous carcinoma cells), as a result of induction
of the pro-survival gene Bcl-2 and inhibition of apoptosis
(Hakimelahi et al, 2000). In support of the latter idea, mutations
within or near to a glycogen synthase kinase-3b consensus
phosphorylation site have been discovered in advanced hormone
refractory prostate cancer, and these coincide with strong nuclear
accumulation of plakoglobin and a concomitant increase in Bcl-2
(Shiina et al, 2005). By contrast, in early prostate cancer, it appears
to be loss of expression of plakoglobin, as a result of loss of
heterozygosity (LOH) and hypermethylation of the plakoglobin
promoter, that is important (Shiina et al, 2005). Indeed, the
majority of studies suggest that plakoglobin has a tumour
suppressor role. The plakoglobin gene is subjected to LOH in
breast and ovarian cancers (Aberle et al, 1995) and loss of
expression of plakoglobin has been correlated with poor
clinical outcome in a number of cancers including non-small
cell lung cancer (Winn et al, 2002). Plakoglobin is a histone
deacetylase target gene and histone deacetylase inhibitors induce
expression of plakoglobin in bladder carcinoma cells (Canes et al,
2005).
Experiments carried out both in vivo and in vitro have provided
further evidence that plakoglobin suppresses proliferation. Trans-
fection of plakoglobin into bladder cancer cell lines that show
reduced levels of the protein reduces migration and suppresses the
ability of the cells to produce tumours in nude mice (Rieger-Christ
et al, 2005). Similarly, re-expression of plakoglobin in lung cancer
cell lines inhibits cell growth on plastic and anchorage-indepen-
dent growth in agar (Winn et al, 2002).
Overall, the evidence clearly supports a role for plakoglobin in
cancer. Whether this is related to its participation in desmosomes
remains unclear. It may be that desmosomes are able to sequester
plakoglobin and so regulate its signalling activity in the same way
that adherens junctions are apparently able to modulate b-catenin
signalling (Gottardi et al, 2001; Kuphal and Behrens, 2006), but
this is by no means is certain. Clearly, more work needs to be
carried out to address this possibility.
OTHER DESMOSOMAL CONSTITUENTS,
WNT/b-CATENIN SIGNALLING AND CANCER
Many reports in the pathology literature have documented
alterations in the expression of desmosomal cadherins during
tumourigenesis, and LOH in the region of the desmosomal
cadherin gene cluster on chromosome 18 has been observed in
oesophageal and head and neck cancer (reviewed by Chidgey,
2002). In some cases, the immunohistochemistry data are contra-
dictory and this may be at least in part due to the use of antibodies
in early studies that do not distinguish between the various
desmocollin and desmoglein gene products. Recent studies have
shown loss of Dsg2 in gastric cancer (Biedermann et al, 2005;
Yashiro et al, 2006), Dsc2 in colorectal cancer (Khan et al,
2006) and Dsc3 in breast cancer (as a result of promoter
hypermethylation) (Oshiro et al, 2005). By contrast, Dsg2 and
Dsg3 are overexpressed in squamous cell cancer of the skin
(Kurzen et al, 2003) and head and neck cancer (Chen et al, 2007),
respectively.
Alterations in the expression patterns of desmosomal cadherins
in cancer could result in the release of plakoglobin from
desmosomes, subsequent displacement of b-catenin from adherens
junctions and increased Wnt/b-catenin signalling (Figure 1).
Support for this idea has come from experiments in transgenic
mice that are either null for Dsc1 (Merritt et al, unpublished) or
overexpress Dsc3 in upper layers of the epidermis (it is normally
expressed in basal layers) (Hardman et al, 2005). The mice exhibit
hyperproliferation in the epidermis, and a redistribution of
b-catenin from the membrane to the nucleus occurs in keratino-
cytes. Furthermore, cultured skin cells exhibit enhanced Topflash
activity. It is perhaps surprising that Wnt/b-catenin signalling is
enhanced in both experimental situations. Nevertheless, these
results raise the possibility that modulation of desmosomal
cadherin expression in cancer could stimulate transcription of
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changes in desmosomal cadherin expression patterns; release of
plakoglobin from desmosomes could result in its translocation to
the nucleus (Figure 1). Whether this would promote proliferation
(by stimulating transcription of genes such as c-myc and Bcl-2) or
have the opposite effect (by acting as a negative regulator of Wnt/
b-catenin signalling) remains uncertain.
Overexpression of either Dsg2 or Dsg3 in suprabasal layers of
mouse epidermis also results in keratinocyte hyperproliferation
(Merritt et al, 2002; Brennan et al, 2007). In the case of Dsg2,
precancerous papillomas appear in the skin of transgenic animals.
Moreover, enhanced activation of multiple growth and survival
pathways, including the phosphatidylinositol 3-kinase, mitogen-
activated protein kinase, STAT3 and NF-kB pathways, is observed
(Brennan et al, 2007). In humans, patients with Dsg1 haploinsuffi-
ciency exhibit thickening of the skin on palms and soles,
presumably as a result of defective adhesion and compensatory
changes in keratinocyte proliferation and differentiation (Hunt
et al, 2001). Overall, these finding indicate that alterations in
desmosomal cadherin expression patterns, perhaps through
modified intracellular signalling and/or changes in adhesive
strength, has fundamental effects on cell behaviour, and can in
some situations drive proliferation.
Alterations in plakophilins have been reported in cancer. PKP3
expression is lost at the invasive front of colorectal cancers (Aigner
et al, 2007). By contrast, its expression is elevated in lung cancer
and overexpression of exogenous PKP3 in COS-7 cells enhances
growth and motility (Furukawa et al, 2005). Loss of expression of
desmoplakin has been correlated with the progression of several
cancers (Chidgey, 2002). PKP2 is able to stimulate Topflash
activity (Chen et al, 2002), whereas loss of desmoplakin can lead to
reduced Topflash activity (following translocation of plakoglobin
to the nucleus) (Garcia-Gras et al, 2006). It appears that
modulation of expression of all desmosomal constituents, includ-
ing desmosomal cadherins, plakoglobin, plakophilins and
desmoplakin, may be able in one way or another to influence
Wnt/b-catenin signalling.
A POTENTIAL ROLE FOR DESMOSOMES IN Rho
SIGNALLING
Desmosomes may affect other signalling pathways. The protein
p0071 (also known as PKP4) exhibits dual localisation in
desmosomes and adherens junctions, at least in some cell types
(Hatzfeld et al, 2003). It shares significant sequence homology with
PKPs1–3, but is more closely related to the adherens junction
protein p120-catenin. The role of p120-catenin in modulating the
activity of Rho GTPases, as well as regulating cadherin turnover at
the membrane, is well established (Reynolds and Roczniak-
Ferguson, 2004). Recent data have now shown that p0071 is also
able to regulate Rho signalling, and it has been proposed that
p120-catenin and related proteins may act as scaffolding proteins
that stabilise Rho signalling complexes (Wolf et al, 2006). Rho
GTPases, which act as molecular switches that control diverse
functions of the cell, have been implicated in tumourigenesis
(Gomez del Pulgar et al, 2005), and the exciting possibility that
desmosomes (via PKPs 1–3 and p0071) could modify their activity
deserves further study.
DESMOSOMES AND THE EPITHELIAL–MESENCHYMAL
TRANSITION
Desmosomes may have an impact on tumourigenesis through their
ability to modify signalling by armadillo proteins (see Figure 1).
They may also be important in cancer progression as a
consequence of their role in the epithelial–mesenchymal transition
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Adherens
junction
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Figure 1 A model outlining how desmosomes could contribute to
tumourigenesis. Unbroken arrows indicate that plakoglobin is released from
desmosomes as a result of either loss or modulation of expression of
desmosomal cadherins or desmoplakin and displaces b-catenin from
adherens junctions. The latter translocates to the nucleus, stimulates
transcription of b-catenin-responsive genes and ultimately results in cell
proliferation. Broken arrows indicate that plakoglobin liberated from
desmosomes translocates to the nucleus, stimulates transcription of genes,
such as c-myc or Bcl-2, and promotes uncontrolled cell growth. Further
possibilities (data not shown) are that loss of expression of plakoglobin
itself could predispose to cancer by reducing its ability to antagonise b-
catenin-mediated Wnt signalling or that plakophilins are involved (see text).
Plakoglobin (yellow), b-catenin (blue), plakophilin (red). a-cat, a-catenin;
DP, desmoplakin; E-cad, E-cadherin; IFs, intermediate filaments.
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Figure 2 Epithelial–mesenchymal transition. Epithelial–mesenchymal
transition in Madin–Darby canine kidney epithelial cells is characterised
by a change in morphology, loss of expression of desmoplakin and gain in
expression of vimentin. DP, desmoplakin.
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mechanism for morphogenesis during embryonic development,
and is implicated in wound healing and conversion of early-stage
tumours into invasive cancers. During EMT, epithelial cells
undergo changes in morphology and acquire the migratory and
invasive characteristics of mesenchymal cells (Figure 2). Disrup-
tion of both adherens junctions and desmosomes must occur for
epithelial cells to dissociate during EMT. A hallmark of EMT in
cancer is loss of expression of the adherens junctions component
E-cadherin, which can occur as a result of genetic and/or
epigenetic mechanisms. Mutations in desmosomal cadherins
have yet to be found in cancer, but loss of expression of
desmosomal cadherins has been documented in a number of
cases (see above).
The closely related zinc-finger transcription factors Snail and
Slug are key EMT regulators that repress E-cadherin expression
during development and cancer. Snail, Slug and the more distantly
related zinc-finger proteins ZEB1 (dEF1) and ZEB2 (SIP1), which
are also strong repressors of E-cadherin, bind to E-box motifs in
the E-cadherin promoter. Transfection of Snail, Slug and ZEB2 into
cultured epithelial cells results in the dissolution of desmosomes
and EMT (e.g., Vandewalle et al, 2005). It may be that desmosome
dissolution occurs simply as a secondary consequence of repres-
sion of E-cadherin. However, recent data have suggested that Slug,
but not Snail, plays an important role in re-epithelialisation by
disrupting desmosomes but not adherens junctions at wound
margins (Savagner et al, 2005). Furthermore, several desmosomal
genes have E-boxes in their promoters and ZEBs 1 and 2 are able to
downregulate expression of PKP2 and PKP3, respectively, by
binding to their promoters (Vandewalle et al, 2005; Aigner et al,
2007). Thus, it is entirely possible that Snail and related proteins
play an active role in loss of expression of desmosomal
components.
Although by no means definitive, there is some evidence that
suggests that desmosome assembly may cause cells to undergo
EMT reversal, the so-called ‘mesenchymal–epithelial conversion’.
Treatment of squamous cell cancer cells with inhibitors that
block the epidermal growth factor receptor and prevent tyrosine
phosphorylation of desmosomal constituents promotes desmo-
some assembly (but has no effect on E-cadherin expression and
solubility), and this is coincident with a change in morphology
from a fibroblastic to epithelial appearance (Lorch et al, 2004).
Introduction of plakoglobin into SCC9 cells, which are deficient in
both plakoglobin and E-cadherin, has a similar effect (Parker et al,
1998). Transfection of a desmocollin, a desmoglein and plakoglo-
bin into fibroblasts is insufficient to produce bona fide desmo-
somes and does not elicit a change in morphology, but is enough
to inhibit invasive behaviour (Tselepis et al, 1998).
CONCLUSION
Definitive evidence that links desmosomes to cancer is still lacking.
However, a substantial amount of evidence is available that
supports the idea that they are involved in progression of the
disease. Changes in expression of desmosomal constituents have
been documented, and mutations in the plakoglobin gene have
been linked to the pathogenesis of prostate cancer. More studies
that comprehensively document changes in desmosomal constitu-
ents during tumourigenesis are required and future challenges will
include identifying mutations (if any) in other desmosomal
constituents. Defining the role of desmosomes as mediators of
intracellular signal transduction and identifying changes in
signalling pathways that occur in response to alterations in the
normal patterns of expression of desmosomal constituents will be
an important step forward. Understanding the mechanisms that
result in desmosome disruption during EMT will advance our
understanding of this critical cell biological process. Progress in
these areas will lead to a better understanding of the role of
desmosomes in normal tissue homeostasis and malignancy.
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